# Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

> **NCT05719714** · PHASE1,PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Kidney Diseases
- Heart Failure With Preserved Ejection Fraction
- Kidney Diseases
- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin 10 MG [Farxiga]

## Key facts

- **NCT ID:** NCT05719714
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05719714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05719714, "Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05719714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*